Permissionless Innovation.
The article explains the importance of permissionless innovation to the pharmaceutical industry. According to the authors, the industry could benefit from this new approach to research and development. They suggest the creation of rules that apply to platforms that promote innovation and the develop...
| Publicado en: | Communications of the ACM Vol. 58; no. 8; pp. 24 - 27 |
|---|---|
| Autores principales: | , |
| Formato: | Opinion |
| Publicado: |
Association for Computing Machinery
Aug2015
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=hlh&AN=108510819&site=ehost-live header: @attributes: shortDbName: hlh uiTerm: 108510819 longDbName: Humanities International Complete uiTag: AN controlInfo: bkinfo: jinfo: jid: 00010782 ACM jtl: Communications of the ACM issn: 00010782 maglogo: N pubinfo: dt: Aug2015 vid: 58 iid: 8 pid: 68 pub: Association for Computing Machinery artinfo: ui: 108510819 10.1145/2790832 ppf: 24 ppct: 3 formats: tig: atl: Permissionless Innovation. aug: au: Chesbrough, Henry Van Alstyne, Marshall affil: Professor, UC Berkeley’s Haas Business School Professor of information economics, Boston University Visiting professor, MIT Initiative on the Digital Economy su: Technological innovations Pharmaceutical industry Research & development Pharmaceutical technology Application program interfaces Drug development sug: subj: Technological innovations Pharmaceutical industry Research & development Pharmaceutical technology Application program interfaces Drug development ab: The article explains the importance of permissionless innovation to the pharmaceutical industry. According to the authors, the industry could benefit from this new approach to research and development. They suggest the creation of rules that apply to platforms that promote innovation and the development of technology that benefits from open access like application program interfaces (APIs). The industry is advised to use permissionless innovation to discover new drugs. pubtype: Periodical doctype: Opinion src: R language: English refInfo: copyright: @attributes: flag: Y dt: @attributes: year: 2015 holdings: @attributes: islocal: N |
|---|